Subramanian Sanjay

SEC source: 0001790246-26-000005 · ownership.xml · derivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2036-09-08

F1 · derivative.exercise_date: 25% of the shares subject to this option vests on the one-year anniversary of the grant date with the remainder vesting in equal monthly installments for thirty-six (36) months thereafter, provided the Reporting Person continues to provide continuous services to the Issuer.

SEC source: 0000950170-25-094103 · ownership.xml · derivative · entry 5

Subramanian Sanjay · CIK 0001790246 · SVP, CFO & Head of BD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 145,000 shares

Expires 2035-03-10

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger").

F4 · price: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option

SEC source: 0000950170-25-094103 · ownership.xml · derivative · entry 4

Subramanian Sanjay · CIK 0001790246 · SVP, CFO & Head of BD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 135,000 shares

Expires 2033-03-22

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger").

F4 · price: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option

SEC source: 0000950170-25-094103 · ownership.xml · derivative · entry 3

Subramanian Sanjay · CIK 0001790246 · SVP, CFO & Head of BD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 180,000 shares

Expires 2032-03-20

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger").

F4 · price: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option

SEC source: 0000950170-25-094103 · ownership.xml · derivative · entry 2

Subramanian Sanjay · CIK 0001790246 · SVP, CFO & Head of BD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 38,500 shares

Expires not disclosed

F3 · derivative.exercise_price: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration.

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger").

F3 · price: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration.

SEC source: 0000950170-25-094103 · ownership.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · SVP, CFO & Head of BD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger").

F2 · shares: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.

SEC source: 0000950170-25-090862 · ownership.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · SVP, CFO & Head of BD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,701

F1 · kind: Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of April 1, 2025 through June 25, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on April 1, 2025, the first trading day of the purchase period.

SEC source: 0000950170-25-049386 · ownership.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · SVP, CFO & Head of BD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,888

F1 · kind: Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of October 1, 2024 through March 31, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on March 31, 2025, the last trading day of the purchase period.

SEC source: 0000950170-25-040323 · ownership.xml · derivative · entry 2

Subramanian Sanjay · CIK 0001790246 · SVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,500

Underlying: Common Stock · 38,500 shares

Expires not disclosed

F3 · derivative.exercise_price: The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028.

F3 · derivative.exercise_date: The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028.

F3 · derivative.expiration_date: The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028.

SEC source: 0000950170-25-040323 · ownership.xml · derivative · entry 1

Subramanian Sanjay · CIK 0001790246 · SVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,000

Underlying: Common Stock · 145,000 shares

Expires 2035-03-10

F1 · derivative.exercise_price: The exercise price represents the closing price of the Issuer's common stock on March 11, 2025.

F2 · derivative.exercise_date: The option was granted on March 11, 2025 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date.

SEC source: 0000950170-24-031876 · ownership.xml · derivative · entry 1

Subramanian Sanjay · CIK 0001790246 · SVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,000

Underlying: Common Stock · 165,000 shares

Expires 2034-03-12

F1 · derivative.exercise_date: The option was granted on March 13, 2024 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date.

SEC source: 0001209191-23-051393 · doc4.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · SVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,398

F1 · kind: Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of April 1, 2023 through September 30, 2023. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on September 29, 2023, the last trading day of the purchase period.

SEC source: 0001209191-23-022466 · doc4.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · SVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,079

F1 · kind: Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of October 1, 2022 through March 31, 2023. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on October 3, 2022, the first trading day of the purchase period.

SEC source: 0001209191-23-021202 · doc4.xml · derivative · entry 1

Subramanian Sanjay · CIK 0001790246 · SVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2033-03-22

F1 · derivative.exercise_date: The option was granted on March 23, 2023. The shares underlying the option are scheduled to vest in equal monthly installments from April 23, 2023 through March 23, 2027.

SEC source: 0001209191-22-024916 · doc4.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · SVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,100

SEC source: 0001209191-22-020519 · doc4.xml · derivative · entry 1

Subramanian Sanjay · CIK 0001790246 · SVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2032-03-20

F1 · derivative.exercise_date: The option was granted on March 21, 2022 and is scheduled to vest 25% on the first anniversary of the grant date. The remainder of the shares underlying the option are scheduled to vest in equal monthly installments over the following three years until the fourth anniversary of the grant date.

SEC source: 0001062993-22-000700 · form4.xml · derivative · entry 2

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 454,007

Underlying: Common Stock · 454,007 shares

Expires 2032-01-03

F2 · derivative.exercise_date: The option vests annually in equal installments over three years commencing on January 3, 2023, subject to continued employment with the Company on the applicable vesting dates.

SEC source: 0001062993-22-000700 · form4.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,125

F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Ocugen Inc.'s (the "Company's") common stock. The restricted stock units vest annually in three equal installments commencing on January 3, 2023, subject to continued employment with the Company on the applicable vesting dates. The restricted stock units will be settled on each applicable vesting date in shares of the Company's common stock.

SEC source: 0001104659-21-151346 · tm2135818-10_4seq1.xml · derivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,120

Underlying: Common Stock · 35,560 shares

Expires 2031-04-19

F1 · derivative.exercise_price: Represents the closing price of Ocugen, Inc.'s (the "Company") common stock on the date of grant. See footnote 2 below.

F2 · shares: On April 19, 2021, the Reporting Person was granted a performance-based option to purchase 177,800 shares of the Company's common stock based on the Company's satisfaction of five performance criteria prior to the end of the Company's 2021 and 2022 fiscal years, as applicable (the "Performance-Based Option"). With respect to each performance criteria, 10% of the Performance-Based Option vests on the date of the Compensation Committee's determination that the applicable criteria has been achieved (each, a "Determination Date") and an additional 10% vests upon the first anniversary of the applicable Determination Date, subject to the grantee's continued service with the Company on such date.

F3 · shares: On December 16, 2021, the Compensation Committee determined that the second performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 35,560 shares. 17,780 shares of the Performance-Based Option are immediately vested and exercisable, with the remaining 17,780 shares vesting on December 16, 2022, subject to the Reporting Person's continued service with the Company.

F2 · derivative.exercise_date: On April 19, 2021, the Reporting Person was granted a performance-based option to purchase 177,800 shares of the Company's common stock based on the Company's satisfaction of five performance criteria prior to the end of the Company's 2021 and 2022 fiscal years, as applicable (the "Performance-Based Option"). With respect to each performance criteria, 10% of the Performance-Based Option vests on the date of the Compensation Committee's determination that the applicable criteria has been achieved (each, a "Determination Date") and an additional 10% vests upon the first anniversary of the applicable Determination Date, subject to the grantee's continued service with the Company on such date.

F3 · derivative.exercise_date: On December 16, 2021, the Compensation Committee determined that the second performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 35,560 shares. 17,780 shares of the Performance-Based Option are immediately vested and exercisable, with the remaining 17,780 shares vesting on December 16, 2022, subject to the Reporting Person's continued service with the Company.

SEC source: 0001192482-21-000754 · edgar.xml · derivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,560

Underlying: Common Stock · 35,560 shares

Expires 2031-04-19

F1 · derivative.exercise_price: Represents the closing price of Ocugen, Inc.'s (the "Company") common stock on the date of grant. See footnote 2 below.

F2 · shares: On April 19, 2021, the Reporting Person was granted a performance-based option to purchase 177,800 shares of the Company's common stock based on the Company's satisfaction of five performance criteria prior to the end of the Company's 2021 and 2022 fiscal years, as applicable (the "Performance-Based Option"). With respect to each performance criteria, 10% of the Performance-Based Option vests on the date of the Compensation Committee's determination that the applicable criteria has been achieved (each, a "Determination Date") and an additional 10% vests upon the first anniversary of the applicable Determination Date, subject to the grantee's continued service with the Company on such date. On November 16, 2021, the Compensation Committee determined that one of the performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 35,560 shares. 17,780 shares of the Performance-Based Option are immediately vested and exercisable, with the remaining 17,780 shares vesting on November 16, 2022, subject to the Reporting Person's continued service with the Company.

F2 · derivative.exercise_date: On April 19, 2021, the Reporting Person was granted a performance-based option to purchase 177,800 shares of the Company's common stock based on the Company's satisfaction of five performance criteria prior to the end of the Company's 2021 and 2022 fiscal years, as applicable (the "Performance-Based Option"). With respect to each performance criteria, 10% of the Performance-Based Option vests on the date of the Compensation Committee's determination that the applicable criteria has been achieved (each, a "Determination Date") and an additional 10% vests upon the first anniversary of the applicable Determination Date, subject to the grantee's continued service with the Company on such date. On November 16, 2021, the Compensation Committee determined that one of the performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 35,560 shares. 17,780 shares of the Performance-Based Option are immediately vested and exercisable, with the remaining 17,780 shares vesting on November 16, 2022, subject to the Reporting Person's continued service with the Company.

SEC source: 0001879785-21-000013 · edgar.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,591

F1 · shares: This sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001192482-21-000740 · edgar.xml · derivative · entry 3

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,990

Underlying: Common Stock · 7,990 shares

Expires 2029-10-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option, initially representing a right to purchase a total of 23,970 shares, vests and becomes exercisable in equal annual installments over a three year period commencing on October 1, 2020, subject to continued employment with the Company on the applicable vesting dates.

SEC source: 0001192482-21-000740 · edgar.xml · nonDerivative · entry 2

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,591

F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.96 to $9.97. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001192482-21-000740 · edgar.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,581

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001192482-21-000669 · edgar.xml · derivative · entry 3

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 246,170

Underlying: Common Stock · 30,000 shares

Expires 2030-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option, initially representing a right to purchase a total of 369,256 shares, vests and becomes exercisable in equal annual installments over a three year period, commencing on May 5, 2021, subject to continued employment with the Company on the applicable vesting dates.

SEC source: 0001192482-21-000669 · edgar.xml · nonDerivative · entry 2

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,591

F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.18 to $7.28. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001192482-21-000669 · edgar.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,591

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001192482-21-000633 · edgar.xml · derivative · entry 3

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 276,170

Underlying: Common Stock · 31,086 shares

Expires 2030-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The options, initially representing a right to purchase a total of 369,256 shares, vest and become exercisable in equal annual installments over a three year period, commencing on May 5, 2021, subject to continued employment with the Company on the applicable vesting dates.

SEC source: 0001192482-21-000633 · edgar.xml · nonDerivative · entry 2

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,591

F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.66 to $6.77. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001192482-21-000633 · edgar.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,677

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001790246-21-000003 · edgar.xml · derivative · entry 3

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 307,256

Underlying: Common Stock · 31,000 shares

Expires 2030-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option, initially representing a right to purchase a total of 369,256 shares, vests and becomes exercisable in equal annual installments over a three year period, commencing on May 5, 2021, subject to continued employment with the Company on the applicable vesting dates.

SEC source: 0001790246-21-000003 · edgar.xml · nonDerivative · entry 2

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,591

F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $6.96 to $7.07, inclusive.

SEC source: 0001790246-21-000003 · edgar.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,591

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001192482-21-000423 · edgar.xml · derivative · entry 3

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 338,256

Underlying: Common Stock · 31,000 shares

Expires 2030-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option, initially representing a right to purchase a total of 369,256 shares, vests and becomes exercisable in equal annual installments over a three year period, commencing on May 5, 2021, subject to continued employment with the Company on the applicable vesting dates.

SEC source: 0001192482-21-000423 · edgar.xml · nonDerivative · entry 2

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,591

F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.15 to $8.24. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001192482-21-000423 · edgar.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,591

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001192482-21-000394 · edgar.xml · derivative · entry 3

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,980

Underlying: Common Stock · 7,990 shares

Expires 2029-10-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 7,990 shares under the option are exercisable. The option, initially representing a right to purchase a total of 23,970 shares, vests and becomes exercisable in equal annual installments over a three year period.

SEC source: 0001192482-21-000394 · edgar.xml · nonDerivative · entry 2

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,591

F1 · shares: This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.86 to $11.07. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001192482-21-000394 · edgar.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,581

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001192482-21-000125 · edgar.xml · derivative · entry 2

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,183

Underlying: Common Stock · 35,591 shares

Expires 2030-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Options to purchase one third of the shares (35,591 shares of common stock) vested on January 2, 2021. The remaining options will vest annually in equal installments on January 2, 2022 and January 2, 2023, subject to continued employment with the Company on the applicable vesting dates.

SEC source: 0001192482-21-000125 · edgar.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,591

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001192482-21-000021 · edgar.xml · derivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 800,000

Underlying: Common Stock · 800,000 shares

Expires 2031-01-01

F1 · derivative.exercise_date: The option vests annually in equal installments over three years commencing on January 1, 2022, subject to continued employment with the Company on the applicable vesting dates.

SEC source: 0001192482-20-000329 · edgar.xml · derivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 369,256

Underlying: Common Stock · 369,256 shares

Expires 2030-05-05

F1 · derivative.exercise_date: The options will vest annually in equal installments over three years commencing on May 5, 2021, subject to continued employment with the Company on the applicable vesting dates.

SEC source: 0001192482-20-000023 · edgar.xml · derivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,774

Underlying: Common Stock · 106,774 shares

Expires 2030-01-02

F1 · derivative.exercise_date: The options will vest annually in equal installments over three years commencing on January 2, 2021, subject to continued employment with the Company on the applicable vesting dates.

SEC source: 0001192482-19-000445 · edgar.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

SEC source: 0001104659-19-053097 · a4.xml · nonDerivative · entry 1

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · price: The option grant has a ten year term and vests in equal installments on the anniversary date over a three year period.

SEC source: 0001104659-19-053097 · a4.xml · derivative · entry 2

Subramanian Sanjay · CIK 0001790246 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,970

Underlying: Common Stock · 23,970 shares

Expires 2029-10-01

F1 · derivative.exercise_date: The option grant has a ten year term and vests in equal installments on the anniversary date over a three year period.